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Summary
Objective: To determine the within- and between-patient variability in the concentrations of synovial
fluid, serum and urine markers of joint tissue metabolism in a cohort of patients with knee pain and
cartilage changes consistent with early-stage knee osteoarthritis.
Design: Samples of synovial fluid, serum, and urine were obtained from 52 patients on eight different
occasions during 1 year, as part of a clinical trial in patients with cartilage abnormalities and knee pain.
In joint fluid, aggrecan fragments were quantified by dye precipitation and enzyme-linked
immunosorbent assay (ELISA), and matrix metalloproteinases-1 and -3, and tissue inhibitor of
metalloproteinases-1 by sandwich ELISAs. In serum, keratan sulfate was quantified by ELISA. Type I
collagen N-telopeptide cross-links in urine were determined by ELISA.
Results: The degree of cross-sectional variability in marker concentrations did not vary between the
different sampling occasions, and did not differ between the periods of weeks 0 (baseline), 1–4 (treatment)
and 13–26 (follow-up). Both between-patient and within-patient coefficients of variation varied for
markers in different body fluid compartments, with the lowest variability for serum keratan sulfate,
followed by urine type I collagen N-telopeptide crosslinks, and the highest for synovial fluid markers.
For synovial fluid, aggrecan fragments showed the least variability, and matrix metalloproteinases the
highest. One patient with septic arthritis showed a fivefold peak increase in joint fluid aggrecan
fragment concentrations, while the concentration of matrix metalloproteinase-3 increased 100-fold.
Conclusions: Molecular markers of joint tissue metabolism have been suggested as, for example,
outcome measures for clinical trials of disease-modifying drugs in osteoarthritis. This report is the first
to present data on between- and within-patient variability for such molecular markers in three different
body fluid compartments in stable cohort of patients. The availability of such data enables calculations
to determine the number of patients needed in prospective studies using these markers asoutcome
measures.
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Introduction
Critical pathological processes associated with
osteoarthritis (OA) occur in the joint cartilage, but
also in the subchondral bone, synovium and other
soft joint tissues. Because of our limited ability to
sample and monitor these tissues, body fluid
compartments such as joint fluid, blood and urine
might serve as windows on the pathological
processes in the joint.
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The metabolic processes in joint tissues associ-
ated with OA generate products, ‘markers’, which
are released into joint fluid and appear in blood
and urine. Such molecular markers of cartilage
matrix biosynthesis and degradation could be used
to diagnose, prognosticate and monitor joint
diseases, and to identify disease mechanisms on the
molecular level. Other potential markers of the OA
disease process are associated with the increased
production and release to body fluids of new matrix
molecule structures, enzymes or cytokines. For
overviews and further references on molecular
markers of OA and other joint diseases, several
recent reviews are available [1–6].
A basic hypothesis for OA markers is that such
markers reflect the metabolic processes in joint
tissues. However, the relationship between marker
concentration in a body fluid compartment such as
joint fluid, blood or urine with the metabolic
processes in the joint tissues is rather more
complex than might be expected at first glance, and
is influenced by many factors. For example, the
concentration of a marker of joint cartilage matrix
degradation in synovial fluid may depend not only
on the rate of degradation of cartilage matrix, but
also on other factors such as the rate of
elimination, or clearance, of the molecular frag-
ment in question from the joint fluid compartment
[7–9] and the amount of cartilage matrix remaining
in the joint [10]. Since clearance from the joint
fluid compartment may be increased by inflam-
mation [7, 11, 12], differences in the rates of release
of markers from joint cartilage into synovial fluid
between control joints and inflamed joints may be
underestimated. An assessment of the degradation
rate of a cartilage matrix molecule in arthritis,
based solely on the joint fluid concentration of its
fragments, may thus actually lead to an underesti-
mation of its metabolic rate. In spite of these
confounding factors, marker concentrations in
joint fluid in general seem to correlate with the
expected metabolic rate of joint cartilage matrix
molecules, as assessed by other methods in vitro
and in vivo, for review, see [1]. For molecular
markers in serum and urine, additional factors
influence concentrations, such as lymph node,
liver and kidney function. Moreover, the specific
source of the change in serum marker level may be
questioned, due to the contributions of other joints
and tissues to these pools [9]. Thus, serum and
urine markers are often suggested to reflect
systemic changes in, for example, cartilage
metabolism, while joint fluid markers are proposed
to mirror the local joint conditions.
While many investigations thus show significant
differences in mean concentration values (or ratios
between different markers) between the study
groups with only moderate overlap, interpretation
is confounded by the fact that comparisons
between groups are cross-sectional and often
retrospective [13–22]. The predictive power of the
test to discriminate between groups or prognosti-
cate disease progression is only rarely discussed.
Of further concern in these cross-sectional
studies is the requirement for careful patient
characterization and selection, since sub-grouping
may influence the results significantly [23]. Studies
such as these should thus be regarded as
hypothesis-generating, and will require confir-
mation in prospective studies of well-characterized
patient cohorts followed over a time period
sufficiently long to determine disease progression
by an independent ‘gold-standard’, or in studies of
such cohorts treated with, e.g., disease-modifying
OA drugs.
For all suggested uses of markers, but perhaps in
particular for markers used to monitor treatment
response, we shall require knowledge of the
variability both over time in the individual and
between individuals in representative and stable
cohorts of appropriate size. Such data could be
used to calculate the needed number of patients
and the required response to treatment and
number of patients in a clinical trial setting.
Moreover, we will need marker data for age- and
gender-matched groups of joint-healthy and
arthritic individuals at different stages of disease
development. On the basis of such data, sensitivity,
specificity and predictive power for diagnostic and
prognostic tests may be calculated. Only few such
data have yet been presented [24].
The purpose of this study was to examine the
cross-sectional and longitudinal variability in the
concentrations of synovial fluid, serum and urine
markers of joint tissue metabolism in a cohort of
patients with knee pain and cartilage changescon-
sistent with early-stage knee OA.
Materials and Methods
samples
Samples of synovial fluid, serum, and urine were
obtained from 52 patients at eight different
occasions during the course of 1 year, as part of a
double-blind, placebo-controlled clinical trial of
efficacy of intra-articular injections of hyaluronan
in patients with cartilage abnormalities and knee
pain [25]. At each visit (week 0, 1, 2, 3, 4, 13, 26, and
52) synovial fluid was aspirated as completely as
possible from the affected (index) knee joint
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using a para-patellar approach. Thereafter,
10 ml sterile 0.9% saline was injected into the
joint and aspirated after repeated compression of
the infra- and supra-patellar regions. Finally, at
weeks 0, 1, 2, 3, and 4, the trial drug or placebo
(2.5 ml containing 25 mg high molecular weight
hyaluronan or 2.5 ml phosphate-buffered saline
vehicle, respectively) was injected intra-
articularly. At weeks 13, 26, and 52 no drug or
vehicle was injected.
Synovial fluids were collected in EDTA-
containing tubes, centrifuged at 2000 g for 10 min
to remove cells and debris, and aliquots frozen at
- 70° C. Lavage fluids were treated similarly, but
not further analyzed in this study. Blood was
collected in plain tubes, allowed to clot at room
temperature, centrifuged, serum withdrawn and
aliquots frozen at - 70° C until analyzed. Urine was
collected as first morning void, centrifuged at
2000 g for 10 min to remove cells and debris, and
aliquots frozen at - 20° C. Samples not obtained,
lost or of insufficient volume were treated as
missing data in the statistical calculations.
patients
The mean age of the 52 patients in the clinical
trial was 45 years (range 29–64), 18 were females,
mean body mass index was 26.8 (15–36). Of the 52
patients included, nine had a previous cruciate
ligament rupture with or without meniscus lesion,
25 had a previous isolated meniscus lesions, and 18
patients had no history of knee injury.
Radiographs, obtained in a standardized manner
[26] at the time of arthroscopy, did not reveal joint
space narrowing exceeding 50% of the normal
joint space in any of the patients [27]. The mean
medial tibio-femoral compartment joint space
width at baseline was 4.58 mm (range 1.8–6.4 mm)
in the affected knee and 4.82 mm (2.9–7.2 mm) in
the unaffected knee. However, arthroscopy
performed between 2 years and 6 months before
study start, showed cartilage changes in the
affected, painful knee in all patients, consistent
with early-stage OA [28]. The mean total score for
tibiofemoral cartilage changes assessed by
arthroscopy [29] was 6 (range 3–13). With the
Outerbridge score [29], each of the four
tibiofemoral joint surfaces is given a score between
0 and 4 and then summed (0 = all compartments
normal, maximum score 16). A score of at least 2
(representing deep clefts in the cartilage surface)
in one joint surface was required for inclusion in
the study. The mean baseline visual analog scale
value for current knee pain was 48 mm on a 100 mm
scale (range 5–80 mm).
quantification of aggrecan fragments
in synovial fluid
Aggrecan fragments containing the chondroitin
sulfate domain were quantified by dye
precipitation with Alcian Blue [30]. Intra- and
inter-assay coefficients of variation were less than
5%, and the assay was linear between 5 and
400 mg/ml. Results were expressed as equivalents
of adult human joint cartilage aggrecan.
Concentrations of aggrecan fragments in joint
fluid were also assayed by the use of a monoclonal
antibody (1-F21) against a core protein epitope
residing outside the hyaluronan-binding domain of
the adult human aggrecan core protein, possibly in
proximity of the keratan sulfate rich domain, in a
slightly modified competition enzyme-linked
immunosorbent assay (ELISA) [31–32]. Results
were expressed as equivalents of intact adult
human joint cartilage aggrecan. For this assay, the
intra-assay coefficient of variation was 6%, and the
inter-assay coefficient of variation 8%. The linear
range was about 0.02–0.55 mg aggrecan/ml, with
50% inhibition at about 0.06 mg/ml, or about 3 ng
aggrecan per well.
assay of stromelysin (mmp-3), collagenase
(mmp-1) and tissue inhibitor of
metalloproteinases (timp-1) in
synovial fluids and lavage fluids
MMP-1, MMP-3 and TIMP-1 concentrations
were measured by sandwich ELISAs, using
monoclonal and polyclonal antibodies against the
human recombinant proteins, as described
previously [19, 33, 34]. Polyclonal antisera
against the specific proteins, generated in
rabbits, were used as secondary reagents. The
ELISAs for the MMPs detect the proforms of
the enzymes, the large molecular active forms
and the enzymes complexed to TIMP-1, but not
small molecular forms of the enzymes or
enzymes complexed to a2-macroglobulin. The
assay for TIMP-1 detects only free TIMP-1, but
not the inhibitor complexed with MMPs. The
ELISAs have a log-linear relationship between
0.5–100 ng/ml (MMP-3), 2–150 ng/ml (MMP-1), and
0.8–30 ng/ml (TIMP-1). Intra- and inter-assay
coefficients of variation were less than 8% for
these assays. The calculation of molar ratios
between MMP-3 and free TIMP was based on
the assumption, that the major part ( q 90%)
of MMP-3 in human joint fluid is prostromelysin
[34]. Accordingly, the concentrations of
MMP-3, MMP-1 and TIMP-1 are expressed as
molarities(nm) of the human proteins.
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quantification of keratan sulfate in serum
Keratan sulfate concentrations were determined
by an indirect inhibition ELISA based on the use
of the monoclonal antibody ET-4-A-4 [35]. The
assay was performed at pH 5.3, a modification that
yields steeper inhibition curves for unknowns and
standards than at pH 7.0 [36]. Intra- and inter-assay
coefficients of variation were less than 4%. Results
are expressed as equivalents of an international
standard of keratan sulfate purified from human
costal cartilage (a gift from Drs M. B.
Matthewsand and A. L. Horwitz, The University of
Chicago).
quantification of collagen cross-links in
urine
Collagen type I N-telopeptide cross-links (NTx)
in urine were quantified by immunoassay [37].
Results are expressed as picomoles of bone
collagen equivalents per micromole creatinine.
Intra- and inter-assay coecients of variation were
6 and 10%, respectively.
statistical methods
Significance of differences between groups were
determined by Kruskal–Wallis one way analysis of
variance on ranks, with post-hoc comparisons of
subgroups vs. the reference group with Dunn’s
correction for multiple testing. Correlations were
estimated by the Spearman rank correlation test.
A P-value Q 0.05 was considered significant for
differences and correlations, and all differences
and correlations discussed as such are significant
at this level or better.
Results
In this controlled, double-blind, randomized
1-year trial of intra-articular injections of
hyaluronan in 52 patients with knee pain and
articular cartilage abnormalities, both groups
showed significant improvement of symptoms
compared with baseline. However, there was no
difference between the placebo group and the
hyaluronan group for any of the relevant outcome
variables at any time point during the trial [25]. A
standardized radiologic examination was
performed at baseline and after 26 weeks. No
significant differences were found in joint space
width for either the index or contra-lateral knee,
respectively, between these two examinations. The
placebo group and the hyaluronan group did not
differ in any of the baseline characteristics.
Moreover, the two study groups did not differ in
longitudinal variability over time for any of the
markers measured (data not shown). For these
reasons, we have combined the two study groups
for this analysis of synovial fluid concentrations of
markers of joint tissue turnover. One
placebo-treated patient was diagnosed with
Candida arthritis during the course of the trial
[38]. Since the present report is focused on
cross-sectional and longitudinal marker
variability in an otherwise homogenous cohort of
patients with knee pain and articular cartilage
changes diagnosed by arthroscopy, data for this
patient were excluded from the group analysis, and
are shown separately.
Marker assay results are presented for synovial
fluid, serum and urine, but not for lavage fluids.
Average values for volumes of aspirated joint fluid
and concentrations of the different markers in
Table I
Volume of aspirated joint fluid and concentrations of body fluid markers
Mean s.d. Median Min Max
Volume synovial fluid (ml) 4.3 8.4 2 0 65
Volume lavage fluid (ml) 7.7 2.8 8.5 0 18
Aggrecan fragments (mg/ml)* 56.4 25.4 53.0 8.1 202
Aggrecan fragments (mg/ml)† 99.5 57.5 90.0 10.0 414
sf MMP-3 (nm) 22.0 47.3 9.7 0.7 436
sf TIMP-1 (nm) 11.4 10.9 9.0 1.1 121
sf MMP-3:TIMP-1 (nm:nm) 1.4 1.5 1.1 0.2 16.8
sf MMP-1 (nm) 0.20 0.29 0.09 0 2.1
sf MMP-3:MMP-1 (nm:nm) 102 77 80 13.8 495
Serum keratan sulfate (ng/ml) 350 86 343 163 625
Urine collagen I NTx 45.5 22.2 40.4 12 158
sf: synovial fluid.
*Aggrecan fragments assayed by dye precipitation with Alcian Blue [30].
†Aggrecan fragments assayed by dye precipitation with ELISA [31].
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Table II
Between-patient variability in volumes of joint fluid and marker concentrations and ratios at different
sampling occasions
Week 0 1 2 3 4 13 26 52 Average CV% Week 0–52
Joint fluid aspirated 193 180 208 203 206 176 153 116 179
Lavage fluid aspirated 43 23 26 25 34 39 39 36 33
Sf aggrecan fragments* 46 38 43 37 49 46 52 52 45
Sf aggrecan fragments† 56 53 58 50 49 75 57 58 57
Sf MMP-3 249 170 211 211 249 135 180 179 198
Sf TIMP-1 107 78 124 69 115 54 64 48 83
Sf MMP-3:TIMP-1 97 98 143 84 74 81 122 91 99
Sf MMP-1 139 133 154 150 158 139 146 134 144
Sf MMP-3:MMP-1 77 61 75 67 89 61 80 82 74
Number of samples 49 51 47 49 49 43 43 42 –
Serum keratan sulfate 24 24 26 26 26 25 23 23 25
Number of samples 50 51 50 48 50 50 48 45 –
Urine collagen I NTx 47 53 47 45 47 50 48 54 48
Number of samples 43 46 45 44 47 48 47 42 –
sf] synovial ~uid[
Aggrecan fragments assayed by dye precipitation with Alcian Blue 29[
$Aggrecan fragments assayed by ELISA 20[
Variability is expressed as coef_cient of variation "CV)#\ "standard deviation:mean#099[
synovial fluid, serum and urine are given in
Table I.
between-patient variability of marker
concentrations
The volume of aspirated joint fluid or lavage
fluid did not vary significantly between the eight
different sampling occasions. The degree of
cross-sectional variability in marker concentra-
tions (i.e., variability in marker concentrations
between patients at each separate sampling) did
not vary between the different sampling occasions,
and did not differ between the periods of weeks 0
(baseline), 1–4 and 13–26 (Table II).
The cross-sectional coefficient of variation (CV;
standard deviation/mean) varied for markers in
different body fluid compartments, with the lowest
cross-sectional variability shown for serum
(keratan sulfate), followed by urine (type I collagen
N-telopeptide cross-link), and the highest for
synovial fluid (Table II). For synovial fluid,
aggrecan fragments assayed by dye precipitation
with Alcian Blue, showed the least
between-patient variability, and MMP-3 and
MMP-1 the highest.
within-patient variability of marker
concentrations
The degree of within-patient (longitudinal)
variability at different sampling occasions did not
differ between the two similarly sized groups of
patients treated with intra-articular injections of
Table III
Within-Patient variability of body fluid marker concentrations and ratios for eight
different sampling over one year
Mean CV% s.d. CV% Min CV% Max CV%
Volume joint fluid aspirated 61 25 12 154
Volume lavage fluid aspirated 30 19 7 103
Sf aggrecan fragments* 18 11 6 74
Sf aggrecan fragments† 32 15 8 74
sf MMP-3 46 20 14 91
sf TIMP-1 28 17 5 78
sf MMP-3:TIMP-1 35 19 9 122
sf MMP-1 71 41 1 189
sf MMP-3:MMP-1 44 19 2 90
Serum keratan sulfate 9 3 1 16
Urine collagen I NTx 27 11 9 55
sf] synovial ~uid[
Aggrecan fragments assayed by dye precipitation with Alcian Blue 29[
$Aggrecan fragments assayed by ELISA 20[
Variability is expressed as coefficient of variation (CV%), [(standard deviation/mean) · 100].
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Fig. 1. Within-patient (longitudinal) variability of
concentrations of joint fluid markers. (a) Aggrecan
fragments as assayed by dye precipitation with Alcian
Blue. (b) MMP-3 (stromelysin-1) assayed by ELISA. (c)
Molar ratios of MMP-3 to TIMP-1, assayed by ELISA.
Data are shown as individual values for each patient and
sample, with lines connecting values for each patient.
individual variability of marker
concentrations
A significant part of both the between-patient
and within-patient variability was due to a small
number [2–5] of outliers within the whole group of
51 patients [Fig. 1(a)–(c)]. The remainder of the
patients maintained marker levels within a
comparatively narrow range, as exemplified in
Fig. 1(a)–(c). The use of ratios of concentrations of
markers in synovial fluid decreased the amount of
variability [Fig. 1(c)], compared to concentration
values only [Fig. 1(b)].
marker concentrations in a patient with
septic arthritis
Three days before the injection at week 4, this
patient experienced mild pain when walking, and
three days after the fourth injection of placebo
vehicle at week 4, he exhibited a warm and swollen
knee [38]. Cultures for synovial fluid taken at the
time of the fourth injection grew Candida albicans,
and fungicidal treatment was started at week 5 and
continued until week 15 (Fig. 2). A surgical
synovectomy was performed at week 9. The patient
had recovered clinically 2 months later, and at 1.5
and 5 years he showed no apparent effects of the
previous septic knee arthritis.
At week 4, concomitant with the first symptoms
of arthritis, concentrations of aggrecan fragments,
MMP-1, MMP-3 and TIMP-1 in synovial fluid were
increased, and reached peak values at about week
6 (Fig. 2). At week 30, levels of these markers had
returned to baseline. Serum and urine samples
were available only up to week 4, and at that time
showed an increase in urine collagen type I
N-telopeptide cross-link, but no increase in serum
keratan sulfate (data not shown). At week 4, the
concentration of aggrecan fragments in joint fluid
was increased three to sixfold over that of the
other 51 patients, while the concentration of
MMP-3 was increased about 12-fold. At week 6,
when concentrations were highest, the
corresponding ratios were about 5 for aggrecan
fragments and 100 for MMP-3. If the increased
volumes of joint fluid due to the arthritis are taken
into account, the peak total mass ratios at week 6
of aggrecan fragments and MMP-3 in joint fluid
were about 100 and 2500, respectively, compared to
the other patients. Responsiveness to change
(effect size) for an outcome measure may be
estimated by dividing change in concentration or
mass of the marker with the standard deviation of
the baseline concentration [39]. Thus calculated,
the effect sizes for aggrecan fragment and MMP-3
hyaluronan or placebo vehicle (data not shown).
The longitudinal coefficient of variation for the
different body fluid compartments was again low
for serum (9% for keratan sulfate), and highest for
joint fluid (18–71%) (Table III).
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Fig. 2. Joint fluid marker concentrations for a patient with septic arthritis. Results for the arthritis patient (W) are
shown together with average results for the remaining 51 patients in the trial group (w). Bars for trial group show
95% confidence intervals, which are sometimes smaller than size of symbol [panels (b), (c) and (e)]. (a) Aggrecan
fragments assayed by dye precipitation, (b) MMP-3, (c) MMP-1, (d) TIMP-1, (e) molar ratio MMP-3:TIMP-1. Units on
time axis are weeks from trial start. Note logarithmic time axis, and absence of axis break between 0 and 1 weeks.
Data for aggrecan fragments from [38], with permission.
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concentration changes in joint fluid were
approximately 10 and 35, respectively. When the
volumes of joint fluid aspirated were used to
calculate mass of marker aspirated, the effect sizes
became correspondingly greater.
Discussion
The particular markers assayed in this study
were chosen as being representative for joint fluid,
serum and urine, respectively. It has been
suggested that aggrecan fragment concentrations
in joint fluid reflect the local metabolism of joint
cartilage aggrecan, while concentrations of joint
fluid MMP and TIMP proteins are influenced by
local production and secretion in synovial
membrane and cartilage [1–2]. The molar ratios
between MMP-3 and TIMP-1 in joint fluid increase
in osteoarthritis and local joint inflammation
[19–20]. Serum keratan sulfate has been
extensively investigated as a putative marker of
systemic cartilage aggrecan metabolism [40].
Finally, the N-telopeptide cross-link of collagen
type I in urine and serum is regarded primarily as
a marker of systemic bone collagen turnover
[41–44].
The concentrations of joint fluid, serum and
urine markers determined for this cohort of
patients with knee pain and cartilage changes are
consistent with previous reports on these markers
in similar patient groups [17, 19–20, 42, 45]. The
methods used for assay of aggrecan fragments have
been shown to correlate very well with values for
aggrecan fragment concentrations in synovial
fluid obtained with other methods based on ELISA
techniques [20, 32].
Previous publications have shown that concen-
trations of markers in joint fluid are influenced by
the diagnosis, disease stage, disease activity and
time after joint injury [10, 19–21, 34], and to some
extent by body mass index [46], but only marginally
by physical activity [47]. Serum markers, such as
keratan sulfate, are also influenced by gender and
age [17, 48–49]. Urine markers of bone metabolism
are influenced by circadian rhythm, gender, age,
and for women pre- or post-menopausal phase
[41–43]. The cohort studied here was stable for
these parameters over the course of the study.
However, the cross-sectional variability for urine
NTx in particular may have been influenced by
the inclusion of both men and pre- and
post-menopausal women.
The fact that the variability in marker
concentrations between patients at each separate
sampling did not differ between the periods of
weeks 0 (baseline), 1–4 and 13–26 shows that
weekly synovial fluid aspiration and lavage,
followed by intra-articular injection of either
hyaluronan or vehicle, does not introduce any
further between-patient variability in marker
levels, compared with baseline or with more
infrequent samplings. These results importantly
suggest that weekly aspiration of joint fluid (and
lavage) does not represent a confounding factor in
longitudinal patient studies using markers such as
these as outcome measures. Further, if these
markers reflect some aspects of joint cartilage and
synovium metabolic activity, then our results
suggest that the series of weekly injections and
lavage did not change joint tissue metabolism or
induce synovitis.
As expected [9], joint fluid markers showed
greater within- and between-patient variability
than did either urine or serum markers. Of the
joint fluid markers, aggrecan fragments had the
least variability [18 (32)% and 45 (57)%,
respectively, for within- and between-patient
coefficient of variation for assay by dye
precipitation (or ELISA)], while metalloproteinase
concentrations showed a greater variability (e.g.,
46 and 198%, respectively, for MMP-3). The
comparable assay characteristics for the different
markers suggest that these differences reflect true
variability in joint fluid concentrations. The two
different assay methods used for aggrecan
fragments showed somewhat different
characteristics, in keeping with their differences
in specificity. The responsiveness to change was
somewhat greater for the ELISA-based assay than
for the assay based on dye precipitation (data not
shown). As previously proposed, the use of ratios
between markers in the same compartment (e.g.,
MMP-3:TIMP-1) decreased variability, and
provided additional information [19, 50]. The low
degree of longitudinal variation of serum keratan
sulfate levels demonstrated in the present cohort
of patients supports the contention that the serum
level of keratan sulfate is relatively stable with
time in normal human adults [51] as well as in OA
patients [49]. Cross-sectional and longitudinal
variability of joint fluid markers following knee
injury was noted, but not calculated in a previous
study [44].
The present report thus is the first to present
between- and within-patient variability for
markers in joint fluid, serum and urine that reflect
metabolism of cartilage, synovium and bone in a
large, well-characterized and stable cohort of
patients with knee cartilage changes, consistent
with early-stage osteoarthritis.
We note that the degree of variability differs
between markers in the same body fluid
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compartment, reflecting a differing degree of
responsiveness to pathologic processes between
the cells and tissues primarily responsible for the
production and release of these markers. An
example is provided by the great differences in
variability between aggrecan fragments, MMP-1
and MMP-3 in joint fluid. While aggrecan fragment
concentrations reflect degradation and synthesis
of joint cartilage aggrecan, MMP concentrations
probably mirror synthesis, secretion and release of
MMPs from both synovium and cartilage, which
apparently may be more responsive to pathogenic
stimuli. Little is known of the mechanisms which
might be responsible for release into joint fluid of
MMPs bound to matrix components. The case of
septic arthritis provides an illustration of such
pathogenic events (Fig. 2), and shows the
relevance of monitoring both baseline variability
and signal magnitude when assessing the
responsiveness to change for a particular marker
and assay. Even though the baseline variability,
‘noise’, for MMP-3 was greater than for aggrecan
fragments, the effect size was greater for MMP-3
than for aggrecan fragments. The responsiveness
(effect size) for MMP-3 as an outcome measure in
this particular case was some fourfold greater than
that for aggrecan fragments. However, we still
have little or no information with regard to
diagnostic specificity for these or any other
markers in OA.
The lower degree of variability of marker
concentrations within patients, as compared to
between patients, emphasizes the importance of
knowledge of, and comparison with, baseline
concentrations in clinical trials which propose to
use joint markers as outcome measures. MMP-3
concentrations in synovial fluid may serve as an
illustration of the use of data such as those
presented here. If a decrease from a baseline
concentration of 22 nm of MMP-3 to a
concentration of 17 nm is taken as a relevant
change (approximately 0.5 standard deviations),
then some 30 patients per treatment arm would be
sufficient to show this change with a power of 80%.
This example does not imply, however, that such a
change would necessarily relate to a change in the
osteoarthritic disease process, or be clinically
relevant.
Molecular markers of joint tissue metabolism
have been suggested as outcome measures for
example clinical trials of disease-modifying drugs
in OA, and for identifying populations at-risk for
rapid disease progression of joint disease. This
report is the first to present data on between- and
within-patient variability for such molecular
markers in three different body fluid compartments
in a stable cohort of patients. The availability of
such data allows, for example, calculations to
determine the needed number of patients in
prospective studies, for a given projected change
in marker level.
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